What is EyePoint, Inc?
engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 26.65M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 24,875 shares $73k | 110,600 shares $52k |
| 6-9months | 24,875 shares $80k | 11,500 shares $20k |
| 9-12months | 6114,981 shares $1.9M | 0 |